登录 注册 会员服务 联系我们

Overcoming Tyrosine Kinase Inhibitor Resistance in Transformed Cell Harboring SEPT9-ABL1 Chimeric Fusion Protein

  • Published:2019-08 Issue:8 Volume:21 Page:788-801
  • ISSN:1476-5586
  • Container-title:Neoplasia
  • language:en
  • Short-container-title:Neoplasia

Author:

Kawai Hidetsugu,Matsushita Hiromichi,Suzuki Rikio,Kitamura Yuka,Ogawa Yoshiaki,Kawada Hiroshi,Ando Kiyoshi

Funder

Ministry of Education, Culture, Sports, Science, and Technology of Japan

Tokai University School of Medicine Project Research

Research and Study Program of Tokai University Educational System General Research Organization

Publisher

Elsevier BV

Subject

Cancer Research

Reference52 articles.

1. ABL1 fusion genes in hematological malignancies: a review;De Braekeleer;Eur J Haematol,2011

2. Biology of chronic myelogenous leukemia—signaling pathways of initiation and transformation;Melo;Hematol Oncol Clin North Am,2004

3. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib;Hochhaus;Leukemia,2008

4. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia;Saglio;N Engl J Med,2010

5. Management of adult Ph-positive acute lymphoblastic leukemia. Hematology Am. So.c Hematol. Educ;Chiaretti;Dent Prog,2015

Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3